These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 6832389)

  • 1. Role of binding in distribution of furosemide: where is nonrenal clearance?
    Branch RA
    Fed Proc; 1983 Apr; 42(6):1699-702. PubMed ID: 6832389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disposition of furosemide in functionally hepatectomized dogs.
    Verbeeck RK; Gerkens JF; Wilkinson GR; Branch RA
    J Pharmacol Exp Ther; 1981 Mar; 216(3):479-83. PubMed ID: 7205627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clearance of furosemide by the gastrointestinal tract.
    Valentine JF; Brater DC; Krejs GJ
    J Pharmacol Exp Ther; 1986 Jan; 236(1):177-80. PubMed ID: 3941391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Saturable first-pass kinetics, plasma protein binding, and the furosemide intricacies.
    Keller F
    Clin Nephrol; 1995 Jan; 43 Suppl 1():S24-6. PubMed ID: 7781201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic clearance of furosemide in the rat.
    Wallin JD; Ryals P; Kaplowitz N
    J Pharmacol Exp Ther; 1977 Jan; 200(1):52-7. PubMed ID: 833762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Furosemide--pharmacokinetics in geriatric patients with multimorbidity].
    Neubig E; Mühlberg W; Platt D
    Z Gerontol; 1984; 17(5):251-60. PubMed ID: 6523981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Furosemide disposition in cirrhotic patients.
    Sawhney VK; Gregory PB; Swezey SE; Blaschke TF
    Gastroenterology; 1981 Dec; 81(6):1012-6. PubMed ID: 7286579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of experimental azotemia on renal clearance of furosemide in the dog.
    Rose HJ; Pruitt AW; McNay JL
    J Pharmacol Exp Ther; 1976 Jan; 196(1):238-47. PubMed ID: 1246013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of plasma protein binding on renal metabolism and dynamics of furosemide in the rabbit.
    Pichette V; Geadah D; du Souich P
    Drug Metab Dispos; 1999 Jan; 27(1):81-5. PubMed ID: 9884313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bucolome, a potent binding inhibitor for furosemide, alters the pharmacokinetics and diuretic effect of furosemide: potential for use of bucolome to restore diuretic response in nephrotic syndrome.
    Takamura N; Maruyama T; Chosa E; Kawai K; Tsutsumi Y; Uryu Y; Yamasaki K; Deguchi T; Otagiri M
    Drug Metab Dispos; 2005 Apr; 33(4):596-602. PubMed ID: 15640375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of furosemide delivery to its site of action.
    Sjöström PA; Kron BG; Odlind BG
    Clin Nephrol; 1995 Jan; 43 Suppl 1():S38-41. PubMed ID: 7781204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacokinetics of furosemide in children with nephrotic syndrome.
    González-Martín G; Bravo I; Ibarra N; Arancibia A
    Int J Clin Pharmacol Ther Toxicol; 1983 Dec; 21(12):598-601. PubMed ID: 6668097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Furosemide disposition in normal and proteinuric rats: urinary drug-protein binding as a determinant of drug excretion.
    Green TP; Mirkin BL
    J Pharmacol Exp Ther; 1981 Jul; 218(1):122-7. PubMed ID: 7241373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic, biliary excretion, and metabolic studies of 14C-furosemide in the rat.
    Prandota J; Pruitt AW
    Xenobiotica; 1991 Jun; 21(6):725-36. PubMed ID: 1949904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro evidence that urine composition affects the fraction of active furosemide in the nephrotic syndrome.
    Voelker JR; Jameson DM; Brater DC
    J Pharmacol Exp Ther; 1989 Sep; 250(3):772-8. PubMed ID: 2778714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of renal sodium and water excretion in the nephrotic syndrome and cirrhosis of the liver.
    Jespersen B
    Dan Med Bull; 1997 Apr; 44(2):191-207. PubMed ID: 9151012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of the overall response to furosemide: pharmacokinetics and pharmacodynamics.
    Brater DC
    Fed Proc; 1983 Apr; 42(6):1711-3. PubMed ID: 6832391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease-induced modifications of drug pharmacokinetics.
    Barre J; Houin G; Brunner F; Bree F; Tillement JP
    Int J Clin Pharmacol Res; 1983; 3(4):215-26. PubMed ID: 6381335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disposition and diuretic effect of furosemide in the nephrotic syndrome.
    Keller E; Hoppe-Seyler G; Schollmeyer P
    Clin Pharmacol Ther; 1982 Oct; 32(4):442-9. PubMed ID: 7116760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of furosemide in patients on peritoneal dialysis.
    Flinn A; Ledger S; Blake P
    CANNT J; 2006; 16(3):40-4. PubMed ID: 17061696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.